MAP3K5 and diabetic kidney disease: The current study demonstrates that these therapeutic effects are at least partly due to a reduction in tubular senescence and production of SASPs, thereby providing new mechanistic insight into how ASK1 inhibitors protect against DKD and possibly other types of tissue injury.